Rajangam Kanya

SEC source: 0001628280-26-016795 · wk-form4_1773259312.xml · nonDerivative · entry 1

Rajangam Kanya · CIK 0001816676 · Pres. & Chief Med. & Dev. Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,843

F1 · shares: Represents the number of shares of common stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of certain time-based restricted stock unit awards and does not represent an open market sale.

F1 · ownership.direct: Represents the number of shares of common stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of certain time-based restricted stock unit awards and does not represent an open market sale.

SEC source: 0001628280-26-005018 · wk-form4_1770153440.xml · nonDerivative · entry 1

Rajangam Kanya · CIK 0001816676 · Pres. & Chief Med. & Dev. Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,600

F1 · shares: Represents the number of shares of common stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of certain time-based restricted stock unit awards and does not represent an open market sale.

F1 · ownership.direct: Represents the number of shares of common stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of certain time-based restricted stock unit awards and does not represent an open market sale.

SEC source: 0001854270-25-000034 · wk-form4_1741724618.xml · derivative · entry 3

Rajangam Kanya · CIK 0001816676 · Pres. & Chief Med. & Dev. Off.

10b5-1 filing: No plan indicated

Ownership: Indirect · Iyer Family Revocable Trust dated Aug 26 2012

Disclosed balance after: 0

Underlying: Common Stock · 33,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock have no expiration date.

F1 · ownership.nature: The reporting person and her spouse are trustees of the Iyer Family Revocable Trust dated Aug 26 2012. Each of the reporting person and her spouse have voting and dispositive power over the Series A Preferred Stock, Common Stock and Warrants. The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001854270-25-000034 · wk-form4_1741724618.xml · nonDerivative · entry 1

Rajangam Kanya · CIK 0001816676 · Pres. & Chief Med. & Dev. Off.

10b5-1 filing: No plan indicated

Ownership: Indirect · Iyer Family Revocable Trust dated Aug 26 2012

Disclosed balance after: 33,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The reporting person and her spouse are trustees of the Iyer Family Revocable Trust dated Aug 26 2012. Each of the reporting person and her spouse have voting and dispositive power over the Series A Preferred Stock, Common Stock and Warrants. The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001854270-25-000015 · wk-form4_1741647766.xml · nonDerivative · entry 1

Rajangam Kanya · CIK 0001816676 · Pres. & Chief Med. & Dev. Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,984

F1 · shares: The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Senti Biosciences, Inc. 2022 Equity Incentive Plan, as amended and restated (the "Amended and Restated Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. All of the shares underlying the award vest in three substantially equal annual installments over three years from March 7, 2025, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001854270-25-000015 · wk-form4_1741647766.xml · derivative · entry 2

Rajangam Kanya · CIK 0001816676 · Pres. & Chief Med. & Dev. Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 235,088

Underlying: Common Stock · 235,088 shares

Expires 2034-12-19

F2 · date: The option grant was approved by the Issuer's board of directors on December 20, 2024, subject to shareholder approval of the Amended and Restated Plan, under which the option was granted. The Issuer's shareholders approved the Amended and Restated Plan on March 6, 2025.

F3 · derivative.exercise_date: Three-forty-eighth of the shares underlying this option vest on March 31, 2025 ("Vesting Commencement Date") and thereafter one-forty-eighth of the shares underlying this option vest in equal monthly installments from the Vesting Commencement Date, such that the option will be fully vested on the date forty-five months after the Vesting Commencement Date, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001854270-25-000002 · wk-form4_1738889580.xml · nonDerivative · entry 2

Rajangam Kanya · CIK 0001816676 · Pres. & Chief Med. & Dev. Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,621

F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001854270-25-000002 · wk-form4_1738889580.xml · nonDerivative · entry 1

Rajangam Kanya · CIK 0001816676 · Pres. & Chief Med. & Dev. Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,803

F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001854270-24-000121 · wk-form4_1733865346.xml · derivative · entry 2

Rajangam Kanya · CIK 0001816676 · Pres. & Chief Med. & Dev. Off.

10b5-1 filing: No plan indicated

Ownership: Indirect · Iyer Family Revocable Trust dated Aug 26 2012

Disclosed balance after: 49,500

Underlying: Common Stock · 49,500 shares

Expires not disclosed

F5 · derivative.exercise_price: The warrant is exercisable for Common Stock at an exercise price per share equal to $2.30 (subject to adjustment as set forth in the warrant attached as Exhibit 4.1 to the Form 8-K) (the "Warrant"). The Warrant is exercisable at any time and from time to time on or after the Stockholder Approval (as defined in the Warrant) and on or prior to the five year anniversary of the original issuance date. The Warrant cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the U.S. Securities Exchange Act of 1934, as amended, more than 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.

F5 · derivative.exercise_date: The warrant is exercisable for Common Stock at an exercise price per share equal to $2.30 (subject to adjustment as set forth in the warrant attached as Exhibit 4.1 to the Form 8-K) (the "Warrant"). The Warrant is exercisable at any time and from time to time on or after the Stockholder Approval (as defined in the Warrant) and on or prior to the five year anniversary of the original issuance date. The Warrant cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the U.S. Securities Exchange Act of 1934, as amended, more than 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.

F5 · derivative.expiration_date: The warrant is exercisable for Common Stock at an exercise price per share equal to $2.30 (subject to adjustment as set forth in the warrant attached as Exhibit 4.1 to the Form 8-K) (the "Warrant"). The Warrant is exercisable at any time and from time to time on or after the Stockholder Approval (as defined in the Warrant) and on or prior to the five year anniversary of the original issuance date. The Warrant cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the U.S. Securities Exchange Act of 1934, as amended, more than 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.

F4 · ownership.nature: The reporting person and her spouse are trustees of the Iyer Family Revocable Trust dated Aug 26 2012. Each of the reporting person and her spouse have voting and dispositive power over the Series A Preferred Stock, Common Stock and Warrants. The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001854270-24-000121 · wk-form4_1733865346.xml · derivative · entry 1

Rajangam Kanya · CIK 0001816676 · Pres. & Chief Med. & Dev. Off.

10b5-1 filing: No plan indicated

Ownership: Indirect · Iyer Family Revocable Trust dated Aug 26 2012

Disclosed balance after: 33

Underlying: Common Stock · 33,000 shares

Expires not disclosed

F1 · derivative.exercise_price: The Conversion Price of the Series A Preferred Stock is subject to adjustment as set forth in that certain of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock attached as Exhibit 3.1 (the "Certificate of Designation") to the Issuer's Form 8-K filed with the Securities and Exchange Commission on December 2, 2024 (the "Form 8-K"). Capitalized terms that are used but not defined in this Form 4 have the meanings given to them in the Certificate of Designation.

F2 · derivative.exercise_date: The shares of Series A Preferred Stock are not convertible until the stockholders of the Issuer approve the Proposals as set forth in Section 8 of the Certificate of Designation. Additionally, on the Automatic Conversion Date, as set forth in the Certificate of Designation, each share of Series A Preferred Stock shall automatically convert into 1,000 shares of Common Stock.

F3 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock have no expiration date.

F2 · derivative.underlying: The shares of Series A Preferred Stock are not convertible until the stockholders of the Issuer approve the Proposals as set forth in Section 8 of the Certificate of Designation. Additionally, on the Automatic Conversion Date, as set forth in the Certificate of Designation, each share of Series A Preferred Stock shall automatically convert into 1,000 shares of Common Stock.

F2 · derivative.underlying_shares: The shares of Series A Preferred Stock are not convertible until the stockholders of the Issuer approve the Proposals as set forth in Section 8 of the Certificate of Designation. Additionally, on the Automatic Conversion Date, as set forth in the Certificate of Designation, each share of Series A Preferred Stock shall automatically convert into 1,000 shares of Common Stock.

F4 · ownership.nature: The reporting person and her spouse are trustees of the Iyer Family Revocable Trust dated Aug 26 2012. Each of the reporting person and her spouse have voting and dispositive power over the Series A Preferred Stock, Common Stock and Warrants. The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-018927 · form4-07022024_040710.xml · derivative · entry 1

Rajangam Kanya · CIK 0001816676 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,770

Underlying: Common Stock · 12,770 shares

Expires 2034-06-02

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 3, 2025 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

SEC source: 0001854270-24-000017 · wk-form4_1706912927.xml · derivative · entry 2

Rajangam Kanya · CIK 0001816676 · Chief Medical & Devt. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 152,000

Underlying: Common Stock · 152,000 shares

Expires 2034-01-31

F2 · derivative.exercise_date: The shares underlying this option vest in 48 substantially equal monthly installments over four years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001854270-24-000017 · wk-form4_1706912927.xml · nonDerivative · entry 1

Rajangam Kanya · CIK 0001816676 · Chief Medical & Devt. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,000

F1 · shares: The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Senti Biosciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. All of the shares underlying the award vest in three substantially equal annual installments over three years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001209191-23-053006 · doc4.xml · derivative · entry 1

Rajangam Kanya · CIK 0001816676 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,012

Underlying: Common Stock · 8,012 shares

Expires 2033-10-15

F1 · derivative.exercise_date: Thirty three and thirty three one hundreds percent (33.33%) (and thirty three and thirty four one hundreds percent (33.34%) for year three) of the shares subject to the option will vest in three (3) annual installments commencing on the date of the first annual general meeting of stockholders occurring after October 12, 2023, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001854270-23-000018 · wf-form4_167537642370409.xml · derivative · entry 1

Rajangam Kanya · CIK 0001816676 · Chief Medical & Devt. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 130,000 shares

Expires 2033-01-31

F1 · derivative.exercise_date: The shares underlying this option vest in 48 substantially equal monthly installments over four years from February 1, 2023, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0000899243-22-026420 · doc4.xml · derivative · entry 1

Rajangam Kanya · CIK 0001816676 · Chief Medical & Devt. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 327,750

Underlying: Common Stock · 327,750 shares

Expires 2032-07-17

F1 · derivative.exercise_date: 25% of the shares underlying this option vest on July 5, 2023 and the remainder vest in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001209191-22-003756 · doc4.xml · derivative · entry 2

Rajangam Kanya · CIK 0001816676 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,800

Underlying: Common Stock · 76,800 shares

Expires 2032-01-13

F2 · derivative.exercise_date: This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 14, 2022.

SEC source: 0001209191-22-003756 · doc4.xml · nonDerivative · entry 1

Rajangam Kanya · CIK 0001816676 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,800

F1 · shares: Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

SEC source: 0000899243-21-032196 · doc4.xml · derivative · entry 3

Rajangam Kanya · CIK 0001816676 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,054

Underlying: Common Stock · 10,000 shares

Expires 2028-12-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 90 days prior to the trading date.

F3 · derivative.exercise_date: The options exercised were fully vested. Unvested options will vest and become exercisable ratably in monthly installments until fully vested on December 3, 2022.

SEC source: 0000899243-21-032196 · doc4.xml · nonDerivative · entry 2

Rajangam Kanya · CIK 0001816676 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 90 days prior to the trading date.

F2 · price: This transaction was executed in multiple trades at prices ranging from $37.02 to $37.63, inclusive. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0000899243-21-032196 · doc4.xml · nonDerivative · entry 1

Rajangam Kanya · CIK 0001816676 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 90 days prior to the trading date.

SEC source: 0000899243-21-001468 · doc4.xml · derivative · entry 1

Rajangam Kanya · CIK 0001816676 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,500

Underlying: Common Stock · 52,500 shares

Expires 2031-01-07

F1 · derivative.exercise_date: This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 8, 2021.

SEC source: 0000899243-20-019030 · doc4.xml · derivative · entry 1

Rajangam Kanya · CIK 0001816676 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,600

Underlying: Common Stock · 70,600 shares

Expires 2030-07-08

F1 · derivative.exercise_date: This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following July 9, 2020. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement).